PDCD1 and cancer: In comparison to standard chemotherapy, a significant survival benefit was noted in previously treated advanced NSCLC patients receiving anti-PD-1 antibody (3, 4), suggesting that PD-1-mediated T cell exhaustion is a major factor in cancer progression.